Kiniksa Pharmaceuticals International, PLC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Kiniksa Pharmaceuticals International, plc has scheduled its 2026 Annual Meeting of Shareholders for May 29, 2026, to address director re-elections, auditor appointments, and executive compensation.
NASDAQ
Kiniksa Pharmaceuticals International, PLC is urging shareholders to approve two critical proposals at its upcoming Annual Meeting to grant the Board authority to allot shares and disapply pre-emptive rights, citing competitive disadvantages against US-domiciled companies if not approved.
NASDAQ
DEFA14A: Kiniksa Pharmaceuticals Corrects Executive Compensation Disclosures in Proxy Statement Supplement
Kiniksa Pharmaceuticals issues a supplement to its definitive proxy statement to correct errors in the Summary Compensation Table related to certain components of Chief Commercial Officer Ross Moats' compensation.
NASDAQ
DEFA14A: Kiniksa Pharmaceuticals International, PLC Announces 2025 Annual General Meeting and Proxy Statement
Kiniksa Pharmaceuticals International, PLC has scheduled its Annual General Meeting for June 3, 2025, and is providing shareholders with proxy materials for voting on key proposals.
NASDAQ
Kiniksa Pharmaceuticals International, plc will hold its 2025 Annual Meeting of Shareholders on June 3, 2025, to vote on director elections, auditor appointments, executive compensation, and other corporate matters.
NASDAQ
Kiniksa Pharmaceuticals is reminding shareholders to vote for both the Annual General Meeting and the Special Court-Ordered Meeting scheduled for June 5, 2024.
NASDAQ
DEFA14A: Kiniksa Pharmaceuticals Sets Date for Special Court-Ordered Meeting to Vote on Scheme of Arrangement
Kiniksa Pharmaceuticals has scheduled a special court-ordered meeting on June 5, 2024, for shareholders to vote on a proposed Scheme of Arrangement.
NASDAQ
Kiniksa Pharmaceuticals announces its 2024 Annual Meeting of Shareholders to be held virtually on June 5, 2024, with voting open until June 4, 2024.
NASDAQ
Kiniksa Pharmaceuticals is seeking shareholder approval to change its place of incorporation from Bermuda to the United Kingdom, alongside routine annual meeting matters.
NASDAQ
Kiniksa Pharmaceuticals plans to redomicile from Bermuda to the UK, seeking shareholder approval for the move.
NASDAQ
Kiniksa Pharmaceuticals intends to change its place of incorporation from Bermuda to the United Kingdom, pending shareholder and court approval.